Clinical Trial Update: Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bortezomib and rituximab in Waldenström's macroglobulinemia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2018-01-26